Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Project Oncology®

Emerging Metastatic Breast Cancer Therapies: From CDK Inhibitors to SERDs and Beyond

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    There’s been a tremendous amount of clinical research looking at the development of new treatments for metastatic breast cancer. Tune in to hear Dr. Sarah Sammons share her insights on these emerging therapies, like CKD inhibitors, selective estrogen receptor degraders (SERDs), and more. Dr. Sammons is an Associate Director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute.

Recommended
Details
Presenters
Comments
  • Overview

    There’s been a tremendous amount of clinical research looking at the development of new treatments for metastatic breast cancer. Tune in to hear Dr. Sarah Sammons share her insights on these emerging therapies, like CKD inhibitors, selective estrogen receptor degraders (SERDs), and more. Dr. Sammons is an Associate Director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute.

Schedule31 Oct 2024